RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
-13.92%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$2.49B
AUM Growth
+$2.49B
(-24%)
Cap. Flow
-$210M
Cap. Flow
% of AUM
-8.44%
Top 10 Holdings %
Top 10 Hldgs %
45.62%
Holding
96
New
13
Increased
17
Reduced
38
Closed
18
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$44.4M |
| 2 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$41M |
| 3 |
Medtronic
MDT
|
$38.2M |
| 4 |
Teva Pharmaceuticals
TEVA
|
$28.2M |
| 5 |
EPZM
Epizyme, Inc
EPZM
|
$27M |
Top Sells
| 1 |
WCG
Wellcare Health Plans, Inc.
WCG
|
$50M |
| 2 |
BLUE
bluebird bio
BLUE
|
$36.8M |
| 3 |
Centene
CNC
|
$32.1M |
| 4 |
NUVA
NuVasive, Inc.
NUVA
|
$31.2M |
| 5 |
Elevance Health
ELV
|
$31.1M |
Sector Composition
| 1 | Healthcare | 95.6% |
| 2 | Financials | 1.69% |
| 3 | Energy | 0.02% |
| 4 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARRY
1
DELISTED
Array Biopharma Inc
ARRY
| $235M | 9.43% | 16,459,128 +552,448 | +3% | +$7.87M |
|
2
Atara Biotherapeutics
ATRA
$84.6M
| $153M | 6.17% | 4,414,617 +195,900 | +5% | +$6.81M |
|
3
Fate Therapeutics
FATE
$120M
| $133M | 5.35% | 10,359,666 | – | – |
|
4
Xencor
XNCR
$580M
| $112M | 4.49% | 3,084,703 +54,560 | +2% | +$1.97M |
|
5
Wave Life Sciences
WVE
$1.53B
| $94.1M | 3.78% | 2,237,607 -35,700 | -2% | -$1.5M |
|
6
argenx
ARGX
$43.6B
| $92.3M | 3.71% | 960,961 -13,545 | -1% | -$1.3M |
|
|
ALLK
7
DELISTED
Allakos
ALLK
| $88.8M | 3.57% | 1,698,648 +238,756 | +16% | +$12.5M |
|
8
Amicus Therapeutics
FOLD
$2.34B
| $79.7M | 3.21% | 8,323,217 -79,400 | -0.9% | -$761K |
|
9
InflaRx
IFRX
$108M
| $74M | 2.98% | 2,035,400 +10,500 | +0.5% | +$382K |
|
|
CLVS
10
DELISTED
Clovis Oncology, Inc.
CLVS
| $72.9M | 2.93% | 4,060,529 +2,282,229 | +128% | +$41M |
|
|
WMGI
11
DELISTED
Wright Medical Group Inc
WMGI
| $69.1M | 2.78% | 2,537,300 +363,600 | +17% | +$9.9M |
|
|
ALDR
12
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $66.7M | 2.68% | 6,505,766 | – | – |
|
13
Regenxbio
RGNX
$451M
| $56.8M | 2.29% | 1,354,742 -301,323 | -18% | -$12.6M |
|
14
Cigna
CI
$80.3B
| $52.3M | 2.11% | 275,610 -94,590 | -26% | -$18M |
|
|
IMGN
15
DELISTED
Immunogen Inc
IMGN
| $52.2M | 2.1% | 10,884,607 -1,424,428 | -12% | -$6.84M |
|
|
BOLD
16
DELISTED
Audentes Therapeutics, Inc
BOLD
| $49.1M | 1.97% | 2,301,667 +58,311 | +3% | +$1.24M |
|
17
LivaNova
LIVN
$3.08B
| $47.1M | 1.89% | 514,987 -84,301 | -14% | -$7.71M |
|
|
18
Bristol-Myers Squibb
BMY
$96B
| $44.4M | 1.79% | +854,700 | New | +$44.4M |
|
19
eHealth
EHTH
$118M
| $41.9M | 1.69% | 1,091,395 -381,200 | -26% | -$14.6M |
|
20
Xeris Biopharma Holdings
XERS
$1.26B
| $41M | 1.65% | 2,412,641 +1 | +0% | +$17 |
|
|
EPZM
21
DELISTED
Epizyme, Inc
EPZM
| $40.9M | 1.64% | 6,637,278 +4,389,089 | +195% | +$27M |
|
22
Scholar Rock
SRRK
$3.14B
| $40.5M | 1.63% | 1,761,407 -11,700 | -0.7% | -$269K |
|
23
Tandem Diabetes Care
TNDM
$845M
| $39.5M | 1.59% | 1,039,750 -29,920 | -3% | -$1.14M |
|
|
24
Medtronic
MDT
$119B
| $38.2M | 1.54% | +419,900 | New | +$38.2M |
|
25
uniQure
QURE
$896M
| $37.6M | 1.51% | 1,303,422 -336,478 | -21% | -$9.7M |
|